NIOSH Current Intelligence Bulletin: Reproductive Risks Associated With Hazardous Drug Exposures in Healthcare Workers and Recommendations for Reducing Exposures, 3601-3602 [2015-01209]

Download as PDF 3601 Federal Register / Vol. 80, No. 15 / Friday, January 23, 2015 / Notices community. The data will be translated for practitioners and others engaged in parent training work. Data that are collected will be stored physically and electronically by the contractors collecting the respective data at their offices. De-identified electronic database(s) will be transferred to CDC. Any hard copies of data will be destroyed after the data has been successfully entered, cleaned and backed up into the database. We anticipate that the surveys will take nurturing relationships and environments for children, then CDC has a resource that can be easily and freely disseminated to communities. Ultimately, the results of the work will be disseminated to researchers, states, and the public. There are no costs to the respondents other than their time. The total estimated annual burden hours are 1,950. between 15 minutes to 45 minutes to complete (depending on which survey is being completed). The proposed data collection fits into the National Center for Injury Prevention and Control Research Agenda Priorities in Preventing Child Maltreatment. Research is essential to ensure effects on parenting are achieved using the new delivery platform. If Essentials for Parenting Toddlers and Preschoolers is successful at increasing positive parenting and safe, stable, ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Number of responses per respondent Average burden per response (in hrs) Total burden (in hrs) Type of respondent Form name Parents (both Natural Navigation [NN] and Guided Navigation [GN] groups). Screening and Demographics Questionnaires. 200 1 15/60 50 Detailed Assessment Measures ...... Core Assessment Measures (Rotating). Parental EFP Skills Knowledge Scale. Parental EFP Skills Usefulness Scale. Therapy Attitude Inventory and System Usability Scale. 200 200 2 16 45/60 15/60 300 800 200 10 15/60 500 200 5 15/60 250 200 1 15/60 50 ........................ ........................ ........................ 1,950 Total ........................................... ........................................................... Leroy A. Richardson, Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. [FR Doc. 2015–01093 Filed 1–22–15; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention (CDC) [CDC–2015–0003, Docket Number NIOSH– 279] NIOSH Current Intelligence Bulletin: Reproductive Risks Associated With Hazardous Drug Exposures in Healthcare Workers and Recommendations for Reducing Exposures National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Request for information and comment. tkelley on DSK3SPTVN1PROD with NOTICES AGENCY: VerDate Sep<11>2014 18:05 Jan 22, 2015 Jkt 235001 The National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention announces the availability of a draft Current Intelligence Bulletin entitled NIOSH Current Intelligence Bulletin: Reproductive Risks Associated with Hazardous Drug Exposures in Healthcare Workers and Recommendations for Reducing Exposures now available for public comment. To view the notice and related materials, visit http:// www.regulations.gov and enter CDC– 2015–0003 in the search field and click ‘‘Search.’’ Public comment period: Electronic or written comments must be received March 24, 2015. ADDRESSES: You may submit comments, identified by CDC–2015–0003 and Docket Number NIOSH–279, by either of the following two methods: • Federal eRulemaking Portal: http:// www.regulations.gov Follow the instructions for submitting comments. • Mail: National Institute for Occupational Safety and Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C–34, Cincinnati, Ohio 45226–1998. Instructions: All information received in response to this notice must include the agency name and docket number [CDC–2015–0003; NIOSH–279]. All SUMMARY: PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 relevant comments received will be posted without change http:// www.regulations.gov, including any personal information provided. All information received in response to this notice will also be available for public examination and copying at the NIOSH Docket Office, 1150 Tusculum Avenue, Room 155, Cincinnati, OH 45226. SUPPLEMENTARY INFORMATION: Background: The NIOSH Current Intelligence Bulletin: Reproductive Risks Associated with Hazardous Drug Exposures in Healthcare Workers and Recommendations for Reducing Exposures reviews and summarizes all published studies on adverse reproductive effects of occupational exposures to antineoplastic drugs. Hazardous drugs, especially antineoplastic drugs, are some of the most potent teratogenic chemicals known. In addition, they can affect germinal cells, reproduction, and exposures can result in spontaneous abortion. This document summarizes results of animal studies, occupational epidemiology studies, as well as adverse effects that have been observed in patients treated with these drugs. While workplaces should be safe for all employees, the unique sensitivity of the developing fetus and the infant who is E:\FR\FM\23JAN1.SGM 23JAN1 3602 Federal Register / Vol. 80, No. 15 / Friday, January 23, 2015 / Notices breastfeeding necessitate the need for extra precautions when these drugs are handled by both males and females who are trying to conceive, women who may become or who are pregnant, and women who are breast feeding. Recommendations for temporary reassignment of duties or alternative duty are included in this guidance document. Information Needs: Additional data and information are needed to assist NIOSH to protect the reproductive health of healthcare workers who come in contact with antineoplastic drugs. Information is needed for: (1) Appropriateness of guidance, (2) Effect on work practices, (3) Confidentiality issues, (4) Financial impact. NIOSH seeks to obtain materials, including published and unpublished reports and research findings, to evaluate: • Relevant publications not included in this document • Institutional and organizational policies in effect • Other relevant information related to this topic References tkelley on DSK3SPTVN1PROD with NOTICES Connor TH, DeBord G, Pretty JR, Oliver MS, Roth TS, Lees PSJ, Krieg EF, Rogers B, Escalante CP, Toennis CA, Clark JC, Johnson B, McDiarmid MA [2010]. Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. J Occup Environ Med 52:1019–1027. Connor TH, Lawson CC, Polovich M, McDiarmid MA [2014]. Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings. JOEM 56: 901–10. Lawson CC, Rocheleau CM, Whelan EA, Lividoti Hibert EN, Grajewski B, Spiegelman D, Rich-Edwards JW [2012]. Occupational exposures among nurses and risk of spontaneous abortions. Am J Obstet Gynecol 206(327):e1–8. FOR FURTHER INFORMATION CONTACT: Thomas H. Connor, NIOSH, Division of Applied Research and Technologies, Robert A. Taft Laboratories, 1090 Tusculum Avenue, MS–C23, Cincinnati, Ohio 45226, Phone: (513) 533–8399, Email: hazardousdrugs@cdc.gov. Dated: January 15, 2015. John Howard, Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. [FR Doc. 2015–01209 Filed 1–22–15; 8:45 am] BILLING CODE 4163–18–P VerDate Sep<11>2014 18:05 Jan 22, 2015 Jkt 235001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [CDC–2015–0002, Docket Number NIOSH– 244–A] Request for Comment on the Second Decade of National Occupational Research Agenda (NORA) National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Request for information and comment. AGENCY: The National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention announces the availability of NIOSH Docket Number 244–A entitled Request for Comment on the Second Decade of NORA for public comment. To view the notice, visit http:// www.regulations.gov and enter CDC– 2015–0002 in the search field and click ‘‘Search.’’ Public comment period: Electronic or written comments must be received by March 24, 2015. ADDRESSES: You may submit comments, identified by CDC–2015–0002 and Docket Number NIOSH–244–A, by either of the following two methods: • Federal eRulemaking Portal: http:// www.regulations.gov Follow the instructions for submitting comments. • Mail: National Institute for Occupational Safety and Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C–34, Cincinnati, Ohio 45226–1998. Instructions: All information received in response to this notice must include the agency name and docket number [CDC–2015–0002; NIOSH–244–A]. All relevant comments received will be posted without change to http:// www.regulations.gov, including any personal information provided. All electronic comments should be formatted in Microsoft Word. All information received in response to this notice will also be available for public examination and copying at the NIOSH Docket Office, 1150 Tusculum Avenue, Room 155, Cincinnati, OH 45226. SUPPLEMENTARY INFORMATION: Background: The National Institute for Occupational Safety and Health (NIOSH) is evaluating the impact of the National Occupational Research Agenda (NORA, http://www.cdc.gov/niosh/ nora/). NORA is a partnership program to stimulate innovative research and SUMMARY: PO 00000 Frm 00056 Fmt 4703 Sfmt 9990 improved workplace practices. Begun in 1996, NORA has become a research framework for NIOSH and the nation. Diverse parties collaborate to identify the most critical issues in workplace safety and health. Partners work together to develop goals and objectives for addressing these needs. Participation in NORA is broad, including stakeholders from universities, large and small businesses, professional societies, government agencies, and worker organizations. The program entered its second decade in 2006 with a new sector based structure to better move research to practice within workplaces. The national agenda is developed and implemented through the NORA Sector Councils. Each Council develops and maintains an agenda for its sector (http://www.cdc.gov/niosh/nora/). The collection of national sector agendas is the agenda for the nation for improvements in occupational safety and health through research and partnerships. Representing all stakeholders, the councils use an open process to set goals, develop strategies, encourage partnerships, and promote improved workplace practices. NIOSH is reviewing the accomplishments of the second decade of NORA and is preparing for the third decade, which will start in 2016. As a part of this review, NIOSH is seeking comments from partners and the public to evaluate the second decade and plan for the third decade of NORA. NIOSH is requesting the following feedback: Please describe the most significant successes and challenges of your engagement with NIOSH during the second decade of NORA (2006 to present). FOR FURTHER INFORMATION CONTACT: Sidney C. Soderholm, Ph.D., NORA Coordinator, CDC—National Institute for Occupational Safety and Health, 395 E St. SW., Suite 9200, Washington, DC 20201 or call (202) 245–0665. This is not a toll free number. Dated: January 15, 2015. John Howard, Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. [FR Doc. 2015–01208 Filed 1–22–15; 8:45 am] BILLING CODE 4163–19–P E:\FR\FM\23JAN1.SGM 23JAN1

Agencies

[Federal Register Volume 80, Number 15 (Friday, January 23, 2015)]
[Notices]
[Pages 3601-3602]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-01209]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention (CDC)

[CDC-2015-0003, Docket Number NIOSH-279]


NIOSH Current Intelligence Bulletin: Reproductive Risks 
Associated With Hazardous Drug Exposures in Healthcare Workers and 
Recommendations for Reducing Exposures

AGENCY: National Institute for Occupational Safety and Health (NIOSH) 
of the Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Request for information and comment.

-----------------------------------------------------------------------

SUMMARY: The National Institute for Occupational Safety and Health of 
the Centers for Disease Control and Prevention announces the 
availability of a draft Current Intelligence Bulletin entitled NIOSH 
Current Intelligence Bulletin: Reproductive Risks Associated with 
Hazardous Drug Exposures in Healthcare Workers and Recommendations for 
Reducing Exposures now available for public comment. To view the notice 
and related materials, visit http://www.regulations.gov and enter CDC-
2015-0003 in the search field and click ``Search.''
    Public comment period: Electronic or written comments must be 
received March 24, 2015.

ADDRESSES: You may submit comments, identified by CDC-2015-0003 and 
Docket Number NIOSH-279, by either of the following two methods:
     Federal eRulemaking Portal: http://www.regulations.gov 
Follow the instructions for submitting comments.
     Mail: National Institute for Occupational Safety and 
Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C-34, Cincinnati, 
Ohio 45226-1998.
    Instructions: All information received in response to this notice 
must include the agency name and docket number [CDC-2015-0003; NIOSH-
279]. All relevant comments received will be posted without change 
http://www.regulations.gov, including any personal information 
provided. All information received in response to this notice will also 
be available for public examination and copying at the NIOSH Docket 
Office, 1150 Tusculum Avenue, Room 155, Cincinnati, OH 45226.

SUPPLEMENTARY INFORMATION:
    Background: The NIOSH Current Intelligence Bulletin: Reproductive 
Risks Associated with Hazardous Drug Exposures in Healthcare Workers 
and Recommendations for Reducing Exposures reviews and summarizes all 
published studies on adverse reproductive effects of occupational 
exposures to antineoplastic drugs. Hazardous drugs, especially 
antineoplastic drugs, are some of the most potent teratogenic chemicals 
known. In addition, they can affect germinal cells, reproduction, and 
exposures can result in spontaneous abortion. This document summarizes 
results of animal studies, occupational epidemiology studies, as well 
as adverse effects that have been observed in patients treated with 
these drugs. While workplaces should be safe for all employees, the 
unique sensitivity of the developing fetus and the infant who is

[[Page 3602]]

breastfeeding necessitate the need for extra precautions when these 
drugs are handled by both males and females who are trying to conceive, 
women who may become or who are pregnant, and women who are breast 
feeding. Recommendations for temporary reassignment of duties or 
alternative duty are included in this guidance document.
    Information Needs: Additional data and information are needed to 
assist NIOSH to protect the reproductive health of healthcare workers 
who come in contact with antineoplastic drugs. Information is needed 
for: (1) Appropriateness of guidance, (2) Effect on work practices, (3) 
Confidentiality issues, (4) Financial impact.
    NIOSH seeks to obtain materials, including published and 
unpublished reports and research findings, to evaluate:
     Relevant publications not included in this document
     Institutional and organizational policies in effect
     Other relevant information related to this topic

References

Connor TH, DeBord G, Pretty JR, Oliver MS, Roth TS, Lees PSJ, Krieg EF, 
Rogers B, Escalante CP, Toennis CA, Clark JC, Johnson B, McDiarmid MA 
[2010]. Evaluation of antineoplastic drug exposure of health care 
workers at three university-based US cancer centers. J Occup Environ 
Med 52:1019-1027.
Connor TH, Lawson CC, Polovich M, McDiarmid MA [2014]. Reproductive 
health risks associated with occupational exposures to antineoplastic 
drugs in health care settings. JOEM 56: 901-10.
Lawson CC, Rocheleau CM, Whelan EA, Lividoti Hibert EN, Grajewski B, 
Spiegelman D, Rich-Edwards JW [2012]. Occupational exposures among 
nurses and risk of spontaneous abortions. Am J Obstet Gynecol 
206(327):e1-8.

FOR FURTHER INFORMATION CONTACT: Thomas H. Connor, NIOSH, Division of 
Applied Research and Technologies, Robert A. Taft Laboratories, 1090 
Tusculum Avenue, MS-C23, Cincinnati, Ohio 45226, Phone: (513) 533-8399, 
Email: hazardousdrugs@cdc.gov.

    Dated: January 15, 2015.
John Howard,
Director, National Institute for Occupational Safety and Health, 
Centers for Disease Control and Prevention.
[FR Doc. 2015-01209 Filed 1-22-15; 8:45 am]
BILLING CODE 4163-18-P